Dr FIONA PEARCE Fiona.Pearce@nottingham.ac.uk
CLINICAL ASSOCIATE PROFESSOR
Dr FIONA PEARCE Fiona.Pearce@nottingham.ac.uk
CLINICAL ASSOCIATE PROFESSOR
Catherine McGrath
Ravinder Sandhu
Jon C. Packham
Richard Watts
Benjamim Rhodes
Al-Jayyousi Reem
Lorraine Harper
Karen Obrenovic
Peter C. Lanyon
Objectives: We aimed to conduct a large audit of routine care for patients with ANCA-associated vasculitis (AAV).
Methods: We invited all 34 hospitals within one health region in England to undertake a retrospective case note audit of all patients newly-diagnosed or treated with Cyclophosphamide or Rituximab for AAV April 2013-December 2014. We compared clinical practice to the BSR guideline for the management of adults with AAV, and use of Rituximab to the NHS England commissioning policy and NICE Technology Appraisal.
Results: We received data from 213 patients. Among 130 newly diagnosed patients, delay from admission to diagnosis ranged from 0-53 days (median 6, IQR 3-10.5) for those diagnosed as in-patients. BVAS score was recorded in 8% at diagnosis. Remission at 6 months was achieved in 83% of patients. 1-year survival was 91.5%. 130 patients received Cyclophosphamide for new-diagnosis or relapse. The correct dose of i.v. cyclophosphamide (within 100mg of the target dose calculated for age, weight and creatinine) was administered in 58%. 25% of patients had an infection requiring hospital admission during or within 6 months of completing their cyclophosphamide therapy. 76 patients received Rituximab for new-diagnosis or relapse. 97% patients met NHS England or NICE eligibility criteria. PJP prophylaxis (recommended in the summary of product characteristics) was given in only 65% of patients.
Conclusion: We identified opportunities to improve care, including compliance with safety standards for delivery of cyclophosphamide. Development of a national treatment protocol / checklist to reduce this heterogeneity in care should be considered as a priority.
Pearce, F., McGrath, C., Sandhu, R., Packham, J. C., Watts, R., Rhodes, B., Reem, A.-J., Harper, L., Obrenovic, K., & Lanyon, P. C. (2018). Outcomes and compliance with standards of care in ANCA-associated vasculitis: insights from a large multi-region audit. Rheumatology Advances in Practice, 2(2), 1-7. https://doi.org/10.1093/rap/rky025
Journal Article Type | Article |
---|---|
Acceptance Date | Jul 4, 2018 |
Online Publication Date | Jul 31, 2018 |
Publication Date | Jul 31, 2018 |
Deposit Date | Jul 11, 2018 |
Publicly Available Date | Oct 31, 2018 |
Journal | Rheumatology Advances in Practice |
Electronic ISSN | 2514-1775 |
Publisher | Oxford University Press |
Peer Reviewed | Peer Reviewed |
Volume | 2 |
Issue | 2 |
Pages | 1-7 |
DOI | https://doi.org/10.1093/rap/rky025 |
Keywords | ANCA-associated vasculitis; Audit; Routine care; Cyclophosphamide; Survival |
Public URL | https://nottingham-repository.worktribe.com/output/945296 |
Publisher URL | https://academic.oup.com/rheumap/advance-article/doi/10.1093/rap/rky025/5062624 |
Contract Date | Jul 11, 2018 |
Outcomes and compliance
(177 Kb)
PDF
Publisher Licence URL
https://creativecommons.org/licenses/by/4.0/
Copyright Statement
Copyright information regarding this work can be found at the following address: http://eprints.nottingham.ac.uk/end_user_agreement.pdf
The incidence of Kawasaki disease using hospital admissions data for England 2006-2021
(2023)
Journal Article
About Repository@Nottingham
Administrator e-mail: discovery-access-systems@nottingham.ac.uk
This application uses the following open-source libraries:
Apache License Version 2.0 (http://www.apache.org/licenses/)
Apache License Version 2.0 (http://www.apache.org/licenses/)
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search